LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Recommendation of “Buy” from Analysts

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $35.40.

Separately, HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, November 7th.

LENZ Therapeutics Stock Down 5.3 %

Shares of NASDAQ:LENZ opened at $25.28 on Monday. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93. The company has a 50-day simple moving average of $28.65 and a 200-day simple moving average of $26.87.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. During the same period last year, the firm earned ($1.33) EPS. Sell-side analysts predict that LENZ Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of LENZ Therapeutics during the 4th quarter worth $29,000. SG Americas Securities LLC purchased a new stake in LENZ Therapeutics during the third quarter worth about $107,000. China Universal Asset Management Co. Ltd. acquired a new position in LENZ Therapeutics during the fourth quarter worth about $168,000. Squarepoint Ops LLC acquired a new stake in shares of LENZ Therapeutics during the 2nd quarter valued at approximately $181,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of LENZ Therapeutics during the 3rd quarter worth approximately $182,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.